Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

160.22 +4.13 (+2.65%)
Delayed Quote Updated: 10:31 AM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
News headline image
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Novartis boasts a 26% net margin and a fortress balance sheet, while Teva's turnaround has returned it to profitability, but at what cost to stability? 
Via The Motley Fool
News headline image
What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It? ↗
Not every international ETF is a can't-miss investment opportunity. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential. 
Via The Motley Fool
Topics ETFs
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout ↗
Via Chartmill
News headline image
VYMI vs. VIGI: Which International Dividend ETF Is Better? ↗
When buying international dividend stocks, diversification is likely the best bet. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings. 
Via The Motley Fool
News headline image
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗
As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities. 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
MissionIRNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5 Billion ADC Acquisition
Via Investor Brand Network
News headline image
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push ↗
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more. 
Via Benzinga
News headline image
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? ↗
Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity. 
Via The Motley Fool
Topics ETFs
News headline image
New Research Says: The Biggest Gains of AI Won't Go to AI Stocks. These 2 ETFs Could Be Better Buys. ↗
The best AI stocks might be in totally different industries, companies, and countries. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
IEFA vs. VXUS: Both Are Cheap. Both Are Broad. Here Is the Key Difference Long-Term Investors Need to Understand. ↗
These international stock ETFs from iShares and Vanguard are very different once you look under the surface. 
Via The Motley Fool
Topics ETFs
News headline image
3 European Stocks to Carry Investors Through the Back Half of 2026 ↗
European stocks are outpacing the S&P 500 in 2026, and ArcelorMittal, Arm Holdings, and Novartis are three Euro Stoxx 50 components with index-beating returns. 
Via MarketBeat
Topics ETFs Stocks
News headline image
Core Restore Founder Ann Peets Announces Bladder Leak Treatments In Charleston
Via Press Release Distribution Service
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
These stocks are better bets to skyrocket than the much-hyped rocket stock. 
Via The Motley Fool
News headline image
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal ↗
Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers. 
Via Benzinga
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years ↗
International stocks are trading for a steep discount, and here's a great way to invest. 
Via The Motley Fool
Topics ETFs Stocks
News headline image
Teva Just Delivered More Good News on Its Biggest Growth Driver. Is the Stock Still a Bargain? ↗
Teva has been building its comeback, and the latest studies on Austedo and Austedo XR will help further that momentum. 
Via The Motley Fool
News headline image
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study ↗
Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy. 
Via Benzinga
News headline image
IXUS vs. IEFA: Which International ETF Is Better for Most Investors? ↗
When buying international ETFs, owning more stocks in more countries might be a better bet. 
Via The Motley Fool
Topics ETFs
News headline image
VXUS Has Delivered Better Returns Than IEFA Over the Past 5 Years. Should It Be in Your Portfolio? ↗
The Vanguard Total International Stock ETF's (VXUS) outperformance stems from where it invests. 
Via The Motley Fool
Topics ETFs
News headline image
Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer... 
Via MarketBeat
News headline image
IEFA: Why This Fund Is One of the Best International ETFs ↗
Yesterday's slow-growing economies might be tomorrow's best places to invest. 
Via The Motley Fool
Topics ETFs
News headline image
Dry eye syndrome drugs Market Size, Industry Report By 2035 ↗
The most recent research report on the "Dry eye syndrome drugs Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic foreca 
Via Talk Markets
Topics Economy
News headline image
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Adding a Healthcare Stock to Your Portfolio? FHLC Offers Broad Coverage While PPH Leads in Returns. ↗
Expense ratios, asset size, and portfolio strategy set these two healthcare ETFs apart, yet their risk and dividend profiles tell a different story. 
Via The Motley Fool
Topics ETFs
News headline image
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking ↗
This little-discussed pipeline program could prove to be a big success. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
59 60 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.